Cantargia announces that the United States Patent and Trademark Office has granted the company’s patent application directed to the product candidate CAN04.
The antibody CAN04 is targeted against the molecule IL1RAP expressed in a large number of cancer diseases. The formal approval follows the intention to grant that USPTO issued in June 2017.
The patent gives protection in USA until 2035. In addition to the patent granted in USA, Cantargia obtained approval in Europe in August 2017. The application has also been submitted in a number of additional territories such as Japan and China. In these territories, examination is ongoing.
“Thanks to the approvals in both Europe and the US, we have a very strong patent position in the most important territories,” says Göran Forsberg, CEO of Cantargia. “We now have approvals regarding the treatment of various cancers with antibodies against IL1RAP in general as well as for the CAN04 antibody”